S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in

Scopus Biopharma Stock Forecast, Price & News

-0.52 (-3.87 %)
(As of 01/21/2021 12:00 AM ET)
Today's Range
Now: $12.92
50-Day Range N/A
52-Week Range
Now: $12.92
Volume80,147 shs
Average Volume116,504 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Scopus BioPharma Inc. develops therapeutics drugs targeting the endocannabinoid system. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December, 2017. The company was incorporated in 2017 and is based in New York, New York.


Overall MarketRank

0.00 out of 5 stars

Medical Sector

1892nd out of 1,926 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:SCPS



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable
-0.52 (-3.87 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SCPS News and Ratings via Email

Sign-up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Scopus Biopharma (NASDAQ:SCPS) Frequently Asked Questions

What stocks does MarketBeat like better than Scopus Biopharma?

Wall Street analysts have given Scopus Biopharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Scopus Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Scopus Biopharma's CEO?

1,448 employees have rated Scopus Biopharma CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Scopus Biopharma's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Scopus Biopharma's key competitors?

Who are Scopus Biopharma's key executives?

Scopus Biopharma's management team includes the following people:
  • Dr. Morris C. Laster, Co-Chairman & CEO (Age 55)
  • Mr. Robert J. Gibson, Vice Chairman, Sec. & Treasurer
  • Mr. Daniel J. Politzer C.F.A., CFO & COO (Age 51)
  • Mr. Ira Scott Greenspan, Sr. Advisor & Director (Age 61)
  • Dr. Aharon Schwartz, Sr. Advisor (Age 77)
  • Mr. David Silberg, Sr. Advisor (Age 71)

What is Scopus Biopharma's stock symbol?

Scopus Biopharma trades on the NASDAQ under the ticker symbol "SCPS."

When does Scopus Biopharma's quiet period expire?

Scopus Biopharma's quiet period expires on Monday, January 25th. Scopus Biopharma had issued 500,000 shares in its IPO on December 16th. The total size of the offering was $2,750,000 based on an initial share price of $5.50. During Scopus Biopharma's quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Scopus Biopharma?

Shares of SCPS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Scopus Biopharma's stock price today?

One share of SCPS stock can currently be purchased for approximately $12.92.

How can I contact Scopus Biopharma?

The company can be reached via phone at 212-479-2513.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.